153 related articles for article (PubMed ID: 36115850)
1. A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19.
Chen CJ; Yang LY; Chang WY; Huang YC; Chiu CH; Shih SR; Huang CG; Huang KA
Nat Commun; 2022 Sep; 13(1):5466. PubMed ID: 36115850
[TBL] [Abstract][Full Text] [Related]
2. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
3. Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial.
Chuang CH; Huang CG; Huang CT; Chen YC; Kung YA; Chen CJ; Chuang TC; Liu CC; Huang PW; Yang SL; Gu PW; Shih SR; Chiu CH
J Clin Virol; 2022 Dec; 157():105328. PubMed ID: 36399969
[TBL] [Abstract][Full Text] [Related]
4. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial.
Estephan L; Lin YC; Lin YT; Chen YH; Pan SC; Hsieh SM; Torkehagen PF; Weng YJ; Cheng HY; Estrada JA; Waits A; Chen C; Lien CE
Vaccine; 2023 May; 41(23):3497-3505. PubMed ID: 37080829
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.
Torales J; Cuenca-Torres O; Barrios L; Armoa-Garcia L; Estigarribia G; Sanabria G; Lin MY; Antonio Estrada J; Estephan L; Cheng HY; Chen C; Janssen R; Lien CE
Vaccine; 2023 Jan; 41(1):109-118. PubMed ID: 36404171
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Liu X; Shaw RH; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dinesh T; England A; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Singh N; Turner DPJ; Turner PJ; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
Lancet; 2021 Sep; 398(10303):856-869. PubMed ID: 34370971
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.
Hsieh SM; Liu MC; Chen YH; Lee WS; Hwang SJ; Cheng SH; Ko WC; Hwang KP; Wang NC; Lee YL; Lin YL; Shih SR; Huang CG; Liao CC; Liang JJ; Chang CS; Chen C; Lien CE; Tai IC; Lin TY
Lancet Respir Med; 2021 Dec; 9(12):1396-1406. PubMed ID: 34655522
[TBL] [Abstract][Full Text] [Related]
9. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine.
Estephan L; Liu LT; Lien CE; Smith ER; Gurwith M; Chen RT;
Vaccine; 2023 Apr; 41(15):2615-2629. PubMed ID: 36925422
[TBL] [Abstract][Full Text] [Related]
10. A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults.
Kulkarni PS; Gunale B; Kohli S; Lalwani S; Tripathy S; Kar S; Raut S; Kulkarni P; Apte A; Bavdekar A; Bhalla HL; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Pryor M; Hamilton S; Thakar M; Sannidhi RS; Baranwal P; Bhamare C; Dharmadhikari A; Gupta M; Poonawalla CS; Shaligram U; Kapse D;
Sci Rep; 2023 Oct; 13(1):16579. PubMed ID: 37789040
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study.
Huang ST; Huang YS; Liu WD; Pan SC; Sun HY; Lien CE; Chen C; Hsieh SM
J Formos Med Assoc; 2023 Nov; 122(11):1165-1173. PubMed ID: 37321955
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
Jin P; Guo X; Chen W; Ma S; Pan H; Dai L; Du P; Wang L; Jin L; Chen Y; Shi F; Liu J; Xu X; Zhang Y; Gao GF; Chen C; Feng J; Li J; Zhu F
PLoS Med; 2022 May; 19(5):e1003953. PubMed ID: 35617368
[TBL] [Abstract][Full Text] [Related]
13. Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222.
Cheng SH; Lin YC; Chen CP; Cheng CY
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298566
[TBL] [Abstract][Full Text] [Related]
14. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
[TBL] [Abstract][Full Text] [Related]
15. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC
J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895
[TBL] [Abstract][Full Text] [Related]
16. Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study.
Hsieh SM; Chang SC; Cheng HY; Shih SR; Lien CE
Infect Dis Ther; 2022 Aug; 11(4):1493-1504. PubMed ID: 35579840
[TBL] [Abstract][Full Text] [Related]
17. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Barrett JR; Belij-Rammerstorfer S; Dold C; Ewer KJ; Folegatti PM; Gilbride C; Halkerston R; Hill J; Jenkin D; Stockdale L; Verheul MK; Aley PK; Angus B; Bellamy D; Berrie E; Bibi S; Bittaye M; Carroll MW; Cavell B; Clutterbuck EA; Edwards N; Flaxman A; Fuskova M; Gorringe A; Hallis B; Kerridge S; Lawrie AM; Linder A; Liu X; Madhavan M; Makinson R; Mellors J; Minassian A; Moore M; Mujadidi Y; Plested E; Poulton I; Ramasamy MN; Robinson H; Rollier CS; Song R; Snape MD; Tarrant R; Taylor S; Thomas KM; Voysey M; Watson MEE; Wright D; Douglas AD; Green CM; Hill AVS; Lambe T; Gilbert S; Pollard AJ;
Nat Med; 2021 Feb; 27(2):279-288. PubMed ID: 33335322
[TBL] [Abstract][Full Text] [Related]
18. SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines.
Roa CC; de Los Reyes MRA; Plennevaux E; Smolenov I; Hu B; Gao F; Ilagan H; Ambrosino D; Siber G; Clemens R; Han HH
Hum Vaccin Immunother; 2024 Dec; 20(1):2301632. PubMed ID: 38206168
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern.
Lien CE; Kuo TY; Lin YJ; Lian WC; Lin MY; Liu LT; Cheng J; Chou YC; Chen C
Clin Infect Dis; 2022 Jun; 74(11):1899-1905. PubMed ID: 34739037
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study.
Tawinprai K; Jungsomsri P; Pinijnai O; Tavonvunchai F; Lievjaroen A; Suwannaroj P; Siripongboonsitti T; Porntharukchareon T; Sornsamdang G; Ungtrakul T
Hum Vaccin Immunother; 2023 Dec; 19(1):2206360. PubMed ID: 37140889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
